A Clinical Trial to Assess the Effectiveness of NRF2 Activator (Oral Sodium-copper- Chlophyllin ) in Locally Advanced Cervical Cancer to Reduce Late Radiotherapy Toxicity.

Inclusion Criteria: * Female subjects aged 18 years or above with histologically proven locally advanced squamous cell or adenocarcinoma of the cervix * Subjects eligible for RT and planned for definitive RT +/- chemotherapy with brachytherapy. * Subjects who exceed the dose constraints of: * Rectum/sigmoid D 2cm³ EQD2 ³ by more than 70 Gy, or * Bladder D 2cm³ EQD2 ³ more than 80 Gy * Subjects with adequate haematological, renal, hepatic and coagulation profiles and laboratory parameters within the following ranges: * Haemoglobin: ≥ 8 g/dl * ANC ≥ 1,500/mm\^3 * Platelet count 100,000/mm\^3 * Creatinine Clearance: ≥ 50 ml/min (as per Cockcroft-Gault formula) * Bilirubin: ≤ 2 x Upper limit of normal (ULN) * AST and ALT: ≤ 1.5 x ULN * Subjects willing and able to comply with all study requirements, including treatment (e.g. able to swallow tablets), timing and/or nature of required assessments * Ability to understand and willingness to sign an informed consent document Exclusion Criteria: * Subjects with known hypersensitivity or contraindication to the study drug or to any known component of the study drug formulation * Subjects with clinically significant decreased hematologic reserves, with major organ failure, severe electrolyte or metabolic abnormalities, any active infection or any other medical condition that may interfere with the ability to receive study treatment * HIV positive patients * Subjects with a history of blood dyscrasias * Subjects consu…